The Autoimmune Gastritis Puzzle: Emerging Cellular Crosstalk and Molecular Pathways Driving Parietal Cell Loss and ECL Cell Hyperplasia
Cells · 10.10.2025 · 14 (20) · 1576
DOI: 10.3390/cells14201576 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 10.10.2025. Verfasst von Sara Massironi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy. Hauptthemen laut MEDLINE: Parietal Cells, Gastric, Gastritis, Autoimmune Diseases, Enterochromaffin-like Cells. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Autoimmune gastritis (AIG) is a chronic, organ-specific autoimmune disease characterized by progressive destruction of gastric parietal cells driven by autoreactive CD4+ T-cells, epithelial stress pathways, and microbial factors. Parietal cell loss results in achlorhydria, intrinsic factor deficiency, and vitamin B12 malabsorption, ultimately leading to pernicious anemia. Compensatory hypergastrinemia promotes enterochromaffin-like (ECL) cell hyperplasia and contributes to the development of type 1 gastric neuroendocrine neoplasms (gNENs). These clinical consequences are well recognized, yet the cellular and molecular mechanisms driving mucosal atrophy and neoplastic transformation remain incompletely defined. Recent advances highlight the role of endoplasmic reticulum stress, impaired autophagy, innate immune effectors, and dysbiosis in perpetuating inflammation and epithelial injury. The frequent coexistence of AIG with other autoimmune disorders further adds to its clinical complexity. Therapeutic options remain limited, spanning vitamin B12 replacement and endoscopic management to emerging targeted approaches. Netazepide, a gastrin/CCK2 receptor antagonist, is the only agent tested in clinical trials, whereas interventions targeting ER stress, autophagy, immune tolerance, or microbiome composition are still in the preclinical stage. Clarifying these mechanisms is crucial to improve biomarker development, optimize surveillance, and identify targeted therapies to prevent neoplastic transformation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy.
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.
- Gastroenterology and Gastrointestinal Endoscopy Division, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy.
- Gastroenterology and Gastrointestinal Endoscopy Division, IRCCS Policlinico San Donato, Piazza Edmondo Malan 2, 20097 San Donato Milanese, Italy.
ORCID-Profile: Sara Massironi, Elena Oriani, Giuseppe Dell'Anna
Zitieren
APA
Massironi, S., Oriani, E., Dell'Anna, G., Danese, S., & Facciotti, F. (2025). The Autoimmune Gastritis Puzzle: Emerging Cellular Crosstalk and Molecular Pathways Driving Parietal Cell Loss and ECL Cell Hyperplasia. Cells, 14(20), 1576. https://doi.org/10.3390/cells14201576
Vancouver
Massironi S, Oriani E, Dell'Anna G, Danese S, Facciotti F. The Autoimmune Gastritis Puzzle: Emerging Cellular Crosstalk and Molecular Pathways Driving Parietal Cell Loss and ECL Cell Hyperplasia. Cells. 2025;14(20):1576. doi:10.3390/cells14201576
BibTeX
@article{Massironi2025,
author = {Massironi, Sara and Oriani, Elena and Dell'Anna, Giuseppe and Danese, Silvio and Facciotti, Federica},
title = {The Autoimmune Gastritis Puzzle: Emerging Cellular Crosstalk and Molecular Pathways Driving Parietal Cell Loss and ECL Cell Hyperplasia},
journal = {Cells},
year = {2025},
volume = {14},
number = {20},
pages = {1576},
doi = {10.3390/cells14201576}
}
EUVIMED